ESR1 and breast carcinoma: Over three decades, the anti-oestrogen tamoxifen has been the endocrine treatment of choice for patients with oestrogen receptor (ERα)-positive breast cancer (Early Breast Cancer Trialists' Collaborative Group, 1998).